Email this article Morbidity, mortality, long-term outcomes and sequelae of the treatment of cancer patients in different countries of the world
- Authors: Garin A.M.1, Bazin I.S1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 21, No 1-2 (2016)
- Pages: 11-17
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40281
- DOI: https://doi.org/10.18821/1028-9984-2015-21-1-11-17
- ID: 40281
Cite item
Full Text
Abstract
Due to the gain in the average life expectancy in developed countries there is increased the incidence rate of malignant neoplasms. According to the forecast of the USA National Cancer Institute in the next 20 years every 2nd American man and every third American woman will get sick with cancer, and therefore oncology should be considered to be the main medical specialty. Molecular characterization of tumors will become routine, and it will provide an opportunity via screening to detect precancerous abnormalities and early forms of cancer. Surgery will become mostly organsaving modality, radical mutilating surgery will go down in history, traditional chemotherapy with low selectivity of action will send to the glue factory. In the arsenal there will stay well-aimed «targeted» drugs hitting right on target mechanisms of the uncontrolled growth of tumor cells and their dissemination.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Avgust M. Garin
N.N. Blokhin Russian Cancer Research Center
Email: agarin@mail.ru
MD, Phd, DSc, Prof., Chief researcher of the Department of clinical pharmacology and chemotherapy of the Research Institute of Clinical Oncology Moscow, 115478, Russian Federation
I. S Bazin
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
References
- Джемал А., Винеус П., Брей Ф., Торре Л., Форман Д., ред. Атлас современной онкологии. 2-е изд. 2014. http://canceratlas.cancer.org/assets/uploads/2015/05/Cancer-Atlas-Russian-Compressed.pdf
- DeSantis C.E., Lin C.C., Mariotto A.B. et al. Cancer treatment and statistics survivorship. CA. Cancer J. Clin. 2014; 64: 251-76.
- Foxhall L.E., Rodrigues M.A. Advances in Cancer Survivorship Management. Springer; 2015.
- Давыдов М.И., Аксель Е.М., ред. Статистика злокачественных новообразований в России и странах СНГ в 2013 году. М.; 2015.
- Hussain M., DiPaola R.S. Clinical Research in Metastatic Prostate Cancer: A Focus on Impact and Value. Educational Book. ASCO; 2015: 17-21.
- Переводчикова Н.П., Стенина М.Б., ред. Лекарственная терапия рака молочной железы. М.: ПРАКТИКА; 2014.
- Abraham J. et al., Eds. The Bethesda Handbook of Clinical Oncology. 4-th Ed. Wolters Kluwer; 2014.
- Сancer Statistics in Japan. 2012.
- Waquar S.N., Subramanian J., Morgenstern D. et al. Chemotherapy of lung cancer. In: Perrys the chemotherapy source book. Ed. M.C. Perry. Wolters Kluwer; 2012.
- Jemal A., Bray F., Center M.M. et al. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
- Garcia M., Jemal A., Ward E.V. Global Cancer Facts and Figures. 2007. American Cancer Society: Atlanta, GA; 2007.
- Chahine G. Gastric cancer in the era of targeted therapy. In: 26 International Congress on Anti-Cancer Treatment. Paris; 2015.
- Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. CA. Cancer J. Clin. 2011; 61 (4): 212-36.
- Chaudry M.A., Winslet M., Eds. Oxford Handbooks in Surgical Oncology. Oxford University Press; 2009.
- Shroff R.T., Abbruzzese J.L. Molecular pathogenesis of pancreatic adenocarcinoma. In: The Molecular Basis of Cancer / Eds J. Mendelsohn, J.W. Gray, P.M. Howley et al. Elsevier Saunders; 2015.
- Physicians Cancer Chemotherapy Drug Manual / Eds E. Chu, V.T. DeVita V.T. Jones & BARTLETT LEARNING; 2014.
- Conroy T., Desseigne F., Ychou M. et al. Group tumeurs digestives of unicancer prodige intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 364 (10): 1817-25.
- Kantarjian N.M., Wolff R.A., Koller C.A., Eds. The M.D. Anderson Manual of Medical Oncology. 2-nd Ed. Mc Graw Hill Medical; 2011.
- Woo H.G., Park F.S., Lee J.S. et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res. 2009; 69 (9): 4059-66.
- Thorgeirsson S.S., Grisham J.W. Liver Cancer. In: Primer of Molecular Biology of Cancer / Eds V.T. Devita, T.S. Lawrence, S.A. Rosenbrg. Wolters Kluwer; 2011.
- Poon T.C., Wong N., Lai P.B., Rattray M., Johnson P.J., Sung J.J. A tumor progression model for hepatocellular carcinoma; bioinformatics analysis of genomic data. Gastroenterology. 2006; 131: 1262-70.
- DeVita V.T., Rose M.G., Lawrence T.S., Rosenberg S.A., eds. Oncology in Primary Care. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2013.
- Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P. et al. An integrated genomic analysis human glioblastoma multiforme. Science. 2008; 321: 1807-12.
- Armenian S.H., Kremer L.C., Sklar C. Approaches to Reduce the Long - Term Burden of Treatment - Related Complications in Survivors of Childhoo Cancer: Educational Book. American Societe of Clinical Oncology; 2015.
- van der Pal H., van Dalen E.C., van Delden E. et al. High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol. 2012; 30: 1429-37.
- Chemaitilly W., Sklar C.A. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol. Metab. Clin. N. Am. 2007; 36: 983-7.
- Green D.M., Kawashima T., Stovall M. et al. Fertility of mail survivors of child cancer: Report from the Childhood Cancer survivor Study. J. Clin. Oncol. 2010; 28: 332-9.
Supplementary files
